Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $142
Barclays Reaffirms Their Buy Rating on Merck & Company (MRK)
J.P. Morgan Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $145
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $130
BofA Securities Initiates Merck & Co(MRK.US) With Buy Rating, Announces Target Price $140
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target
Merck & Co Analyst Ratings
Moderna Continues to Decline as Oppenheimer Latest to Downgrade
Moderna Extends Losses as R&D Day Updates Lead to Downgrades
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $147
BMO Capital Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $150
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $147
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating
Goldman Sachs Maintains Merck & Co(MRK.US) With Buy Rating
Evercore Maintains Merck & Co(MRK.US) With Buy Rating
TD Cowen Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
TD Cowen Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $140
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Merck & Co Analyst Ratings
Citic Securities Initiates Merck & Co. at Buy With $136 Price Target